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Small molecules that modulate stem cell fate and function offer significant opportunities that will allow the full
realization of the therapeutic potential of stem cells. Rational design and screening for small molecules have
identified useful compounds to probe fundamental mechanisms of stem cell self-renewal, differentiation, and
reprogramming and have facilitated the development of cell-based therapies and therapeutic drugs targeting
endogenous stem and progenitor cells for repair and regeneration. Here, we will discuss recent scientific and
therapeutic progress, as well as new perspectives and future challenges for using chemical approaches in
stem cell biology and regenerative medicine.Introduction
Small molecules modulating specific targets involved in
signaling, metabolic, transcriptional, or epigenetic mechanisms
have emerged as valuable tools for probing basic stem cell
biology and manipulating stem cell fate, state, or function
in vitro and in vivo (Schugar et al., 2008; Xu et al., 2008).
Compared to genetic manipulations, small molecules have a
number of distinct advantages: they are more convenient to
use, they provide a higher degree of temporal (e.g., effects are
rapid and reversible) and spatial (e.g., effects are confined
to different cell or tissue compartments) control over protein
function, and their effects can be fine-tuned by varying their
concentrations and combinations. While the specificity of small
molecules often presents a challenge for using them and
interpreting their effects, their polypharmacological mechanisms
can also be exploited for desirable outcomes. Rational designs
and screenings of small molecules to modulate specific targets
or stem cell phenotypes have led to the generation and validation
of useful compounds for enhancing cell-based therapy and
facilitating the development of therapeutic drugs targeting
endogenous stem and progenitor cells to treat degenerative
diseases, cancer, and injuries (Figure 1). As a nascent field,
stem cell research will continue to benefit from its crossover
with chemistry. In this Review, we discuss some of the recent
developments in applying chemical approaches to stem cell
biology and regenerative medicine.
Small Molecules Modulating Stem Cell Maintenance
Pluripotent Stem Cells
Pluripotent stem cells (PSCs) are unique in that they can indefi-
nitely self-renew and give rise to all cell types in the body. The
two most-studied PSC types are the classic murine embryonic
stem cells (mESCs) and human ESCs (hESCs), which represent
two different pluripotency states (i.e., naive versus primed
pluripotency states) and consequently display significant differ-
ences in gene expression and cell behaviors (Li and Ding,270 Cell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc.2011). Identified small molecules that modulate these two types
of PSCs have changed the way they are practically manipulated
in culture as well as our understanding of pluripotency.
mESCs possess an intrinsic ability to self-renew and do not
depend on exogenous pathway activation, a conceptual
advance led by the discovery and characterization of pluripotin
(a novel synthetic small molecule, Figure 2) from a high-
throughput phenotypic screen (Chen et al., 2006). Pluripotin
can maintain the long-term self-renewal of mESCs in the
absence of feeder cells, serum products, and typically used
cytokines (e.g., leukemia inhibitory factor [LIF] and bone
morphogenetic protein 4 [BMP4]) by dual inhibition of two
endogenous differentiation-inducing proteins, Ras GTPase
activating protein (RasGAP) and extracellular signal-regulated
kinase-1 (ERK1), and does so without activating essential
self-renewal pathways, including LIF-STAT3 (signal transducer
and activator of transcription 3), BMP4-Smad, and Wnt-
b-catenin. Subsequent studies showed that 2i, the combination
of a mitogen-activated protein/ERK kinase (MEK) inhibitor
PD0325901 (Figure 2) and a glycogen synthase kinase-3
(GSK3) inhibitor CHIR99021 (Figure 2) (Ying et al., 2008), and
other combinations of factors that inhibit differentiation signaling
pathways in conjunction with LIF treatment can support the
derivation and long-term self-renewal of mESCs (especially
from refractory strains) (Hanna et al., 2009; Yang et al., 2009),
rat ESCs and induced pluripotent stem cells (iPSCs) (Buehr
et al., 2008; Kawamata and Ochiya, 2010; Li et al., 2008,
2009a), and hPSCs that resemble a naive pluripotent state
(Hanna et al., 2010; Li et al., 2009a). The approach of using
small molecules tomaintain PSC self-renewal by inhibiting differ-
entiation mechanisms can also be applied to expand adult
stem cell populations or establish pluripotency through reprog-
ramming (Cao et al., 2013; Li et al., 2011; Shi et al., 2008b; Silva
et al., 2008).
In line with stem cells’ intrinsic self-renewal ability, specific
endogenous smallmolecules derived fromstemcells themselves
Figure 1. Chemical Approaches to Stem
Cell Biology and Therapeutics
Chemical approaches are applied in vitro and
in vivo to manipulate cell fate toward desired
therapeutic applications, which include cell
activation, expansion, differentiation, somatic
lineage-specific transdifferentiation, and iPSC
reprogramming. The functional cells generated
through chemical approaches could be used as
the cell source for cell-based therapy. In addition,
the chemical compounds that can regulate
appropriate cell fate or function could be further
developed as small molecule therapeutics for
modulating endogenous cells underlying disease
or injury conditions.
Cell Stem Cell
Review(e.g., metabolites of cellular essential nutrients and other building
blocks) regulate cell-type-specific signaling, metabolic, tran-
scriptional, and epigenetic mechanisms by participating in pro-
tein modifications or serving as endogenous receptor ligands
or enzyme cofactors (Folmes et al., 2012; Zhang et al., 2012).
For example, mass spectrometry-based untargeted metabolo-
mic profiling of undifferentiated mESCs and their differentiated
neural and cardiac derivatives (Yanes et al., 2010) revealed that
undifferentiated mESCs were characterized by the low oxidative
state of their metabolomes (i.e., enriched with highly unsaturated
metabolites), but when differentiation was induced, the level
of unsaturated metabolites decreased drastically, thereby
increasing the percentage of new hydrogenated and oxygenated
metabolites in differentiated populations. This phenomenon
parallels cell plasticity with endogenous ‘‘chemical plasticity.’’
Significantly, either the addition of certain cell-stage-specific
metabolites or modulation of the corresponding metabolic
pathways consistently promoted stem cell self-renewal or
induced their specific differentiation, thereby demonstrating
how metabolites and metabolic mechanisms control cell fate.
Furthermore, this study illuminated how a switch from glycolysis
in ESCs to oxidative metabolism in differentiated cells orches-
trates the stem cell regulatory network.
Recent studies on hESC survival shed light on how cell adhe-
sion mechanisms control stem cell fate. In contrast to mESCs,
dissociated single hESCs survive poorly, which is problematic
for routine large-scale culture and clonal selection. By screening
a small collection of kinase inhibitors, Watanabe et al. (2007)
initially found that the Rho-associated kinase (ROCK) inhibitor
Y27632 could promote the survival of dissociated hESCs. To
gain a better understanding of the molecular mechanisms
governing hESC survival, we performed a high-throughput
phenotypic screening of 50,000 novel synthetic compounds
to identify small molecules that promote hESC survival after
trypsin dissociation (Xu et al., 2010). From the primary screeningCell Stem Cell 13, Sand subsequent structure-activity rela-
tionship (SAR) study, two distinct potent
compounds—a 2,4-disubstituted thia-
zole (named thiazovivin/Tzv, Figure 2)
and a 2,4-disubstituted pyrimidine
(named Pyrintegrin/Ptn)—were identified
to significantly increase single-cell sur-
vival with enhanced self-renewal. Further
characterization uncovered that Tzv canpromote cell survival in both adherent and suspension culture
conditions, while Ptn promotes cell survival only in adherent
culture conditions. Affinity pull-down experiments using a Tzv-
immobilized matrix (along with other studies) revealed that Tzv
enhances E-cadherin stability and cell-cell interactions through
the inhibition of ROCK, and Ptn regulates cell-extracellular
matrix (ECM) interactions to indirectly enhance E-cadherin.
Remarkably, at the cell surface, the E-cadherin-mediated cell-
cell interactions and integrin-mediated cell-ECM interactions
form a positive feedback regulatory loop via inhibition of Rho-
ROCK signaling pathways to regulate the survival of hESCs.
Concurrent studies also revealed that hESC dissociation (break-
down of E-cadherin interaction) led to a long-lasting apoptotic
cellular contraction due to myosin hyperactivation in a Rho/
ROCK-dependent manner. Inhibition of ROCK or myosin heavy
chain ATPase (by blebbistatin) diminished actomyosin con-
traction and rescued the apoptosis of dissociated hESCs
(Chen et al., 2010a; Ohgushi et al., 2010; Walker et al., 2010).
Interestingly, these cell adhesion mechanisms are also
involved in controlling naive versus primed pluripotency states.
mESCs and hESCs exhibit differences in their use of and depen-
dence on E-cadherin- or integrin-mediated cell-adhesion mech-
anisms, respectively, for cell maintenance. This is in part due to
differences in E-cadherin expression and stability in the two
pluripotency states, which are controlled by the different cell
culture signaling environments. Combinations of overexpressed
pluripotency factors (e.g., Oct4, Klf4, Nanog, E-cadherin, etc.)
with signaling and metabolic modulation (e.g., treatment with
inhibitors of MEK, transforming growth factor b [TGFb] receptor,
GSK3, ROCK, or compounds promoting glycolytic metabolism)
have been shown to promote transition of primed pluripotency
toward naive pluripotency (Chou et al., 2008; Guo et al., 2009;
Hanna et al., 2010; Xu et al., 2010; Zhou et al., 2010). Con-
sequently, cells transitioned toward the naive state rely more
heavily on E-cadherin to mediate cell adhesion and grow in aeptember 5, 2013 ª2013 Elsevier Inc. 271
Figure 2. The Structures and Mechanisms of Representative Chemicals for Cell Fate Modulation
Pluripotin or the combination of PD0325901 and CHIR99021 can support mESC self-renewal by inhibiting the differentiation-inducing signaling. Thiazovivin is a
Rho-associated kinase inhibitor that enhances hESC survival after dissociation. StemRegenin 1 enhances HSC self-renewal by inhibition of aryl hydrocarbon
receptor. SB431542 (a TGFb receptor inhibitor) or other small molecules inhibiting TGFb signaling sustain primitive NSC self-renewal when combined with
CHIR99021 and LIF, promote neural induction from PSCs, or enhance reprogramming. IDE1 promotes differentiation of PSCs into definitive endoderm (DE).
Indolactam V, a protein kinase C activator, promotes differentiation of PSC-derived DE cells toward pancreatic lineage. KY02111, IWR-1endo, and IWP2/4 can
inhibit Wnt signaling through distinct mechanisms and facilitate cardiac specification of PSC-derived cardiac precursor cells. PluriSIn#1 is toxic specifically to
pluripotent cells by inhibiting stearoyl-CoA desaturase-1. Modulation of various epigenetic proteins, including hystone deacetylases, DNA methyltransferases,
histone methyltransferases, histone demethylase, and signaling pathways, including Wnt, cAMP and 30-phosphoinositide-dependent kinase-1, can induce and
enhance reprogramming.
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maintenance. The autoregulatory networks consisting of cell
signaling, metabolic, transcriptional, and adhesion mechanisms
therefore reveal a robustness and coordination of cell fate/state
transition. They also suggest the existence of a wide range of
self-renewal states created by combined differential utilization
of those mechanisms, which exhibit differences in survival,
self-renewal, and differentiation propensity. Practically speak-
ing, creating and maintaining human cells in the naive pluripo-
tency state may allow more robust cell growth and survival,
cell engineering (e.g., enhanced gene targeting efficiency due
to more open chromatin structure and better cell survival under
clonal selection), and a better translation of knowledge gained
on mESCs toward hPSCs. In addition, although recent studies
demonstrated that mouse epiblast stem cells (mEpiSCs) readily
generated chimeras with contributions to all somatic tissues
including primordial germ cells when transplanted to postim-
plantation embryos in whole-embryo culture (Huang et al.,
2012), it is technically more challenging, if not impossible, to
generate genetically manipulated animals using EpiSCs that
cannot efficiently incorporate into the inner cell mass (ICM) of
preimplanted embryos (Brons et al., 2007; Tesar et al., 2007).
Derivation of authentic ICM-stage-like PSCs from species other
than rodents, including nonhuman primates, is highly valuable
and remains to be accomplished.272 Cell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc.Self-Renewal of Tissue-Specific Stem and Progenitor
Cells
Because of their endogenous functions, tissue-specific stem
cells have been long pursued for therapeutic purposes. One
important example is the transplantation of hematopoietic
stem cells (HSCs) from cord blood, bone marrow, or mobilized
peripheral blood for treating a variety of blood disorders (e.g.,
leukemia). However, in contrast to PSCs, it remains a significant
challenge to expand most types of tissue-specific stem and pro-
genitor cells in vitro. For example, one of the main bottlenecks of
HSC transplantation is the difficulty in obtaining sufficient
numbers of immunologically matched HSCs. These deficiencies
reflect our limited understanding of adult stem cell regulation,
especially within their in vivo microenvironment (also called the
stem cell niche) (Watt and Hogan, 2000).
A high-content chemical library screen to examine com-
pounds that affect CD34 and CD133 expression in primary
human CD34+ cells identified a synthetic purine derivative,
StemRegenin 1 (SR1; 5 in Figure 2), which promotes HSC self-
renewal in conjunction with HSC expansion cytokines in vitro
(Boitano et al., 2010). SR1 treatment led to a 50-fold increase
in cells expressing CD34 and a 17-fold increase in cells that
retained the ability to engraft immunodeficient mice. Transcrip-
tome analyses of SR1-regulated gene expression identified a
mechanism whereby SR1 promoted CD34+ cell expansion
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receptor. It is of significant interest to continue exploring and
characterizing the clinical utilities of either SR1-expanded cells
or SR1 itself as a therapeutic agent in vivo.
HSCs reside within a low-perfusion, hypoxic niche in the bone
marrow with restricted nutrients. High dependence on glycolysis
for energy supply is another fundamental characteristic of long-
termHSCs (LT-HSCs). During glycolysis, glucose is converted to
pyruvate and then anaerobically to lactate or aerobically to
acetyl-CoA for use in mitochondrial metabolism. Pyruvate dehy-
drogenase (PDH) catalyzes the conversion of pyruvate to acetyl-
CoA. LT-HSCs express high levels of glycolytic enzymes,
including PDH kinase, which inhibits PDH activation and main-
tains glycolytic flow by suppressing the influx of glycolytic
metabolites into mitochondria. Recently, Takubo et al. (2013)
demonstrated that hypoxia-inducible factor-1a (HIF-1a)-medi-
ated PDH kinase activation is essential to maintain LT-HSC cell
cycle quiescence, stemness, and hematopoietic repopulation
potential after transplantation. In addition, 1-aminoethylphos-
phinic acid (1-AA), a PDH inhibitor, was shown to maintain LT-
HSCs, but not short-term HSCs and multipotent progenitors,
for 4 weeks during in vitro culture under a standard cytokine con-
dition. 1-AA treatment inhibited cell proliferation, but preferen-
tially maintained LT-HSC frequency, suggesting that metabolic
control by PDH kinase may represent a promising strategy to
modulate HSC cell cycle and maintenance (Takubo et al., 2013).
Because it is practically difficult to noninvasively isolate most
types of adult stem cells from specific tissues, the derivation
and expansion of tissue-specific stem cells from PSCs repre-
sent an attractive alternative approach. A recent example
highlights how novel combinations of small molecules could
be developed for expanding primitive neural stem cells
(pNSCs) from hESCs in culture (Li et al., 2011). It was found
that under chemically defined conditions, combining a GSK3
inhibitor (i.e., CHIR99021) with TGFb and Notch signaling
pathway inhibitors induced an efficient conversion of mono-
layer-cultured hESCs into homogenous primitive neuroepithelia
within 1 week. Remarkably, a combination of LIF, CHIR99021,
and the TGFb-receptor inhibitor SB431542 (Figure 2) effectively
captured and enabled these pNSCs to stably self-renew over
the long term following serial passages. The underlying mech-
anisms of this strategy mainly involve the synergy of (1) TGFb/
Activin pathway inhibition that induces neutralization of hESCs
by destabilizing pluripotency and blocking mesendoderm dif-
ferentiation (Pitchford et al., 2009), and (2) GSK3 inhibition
that promotes NSC self-renewal (Kim et al., 2009; Mao et al.,
2009). The generated pNSCs represent pre-rosette-stage neu-
roepithelia, which are distinct from typical basic fibroblast
growth factor (bFGF)-dependent neural precursor cells that
exhibit glial differentiation propensity and restricted response
to morphogens. Notably, the long-term expanded pNSCs
cultured in the appropriate small molecule/LIF treatment condi-
tions maintain their high neurogenic differentiation propensity,
remain highly plastic to instructive regional patterning cues
toward midbrain and hindbrain neuronal subtypes, and exhibit
appropriate in vivo engraftment. Clearly, applying such a strat-
egy to other lineages and developmental stages is a novel area
of research that could lead to the development of new cell-
based therapies.Small Molecules that Induce Stem Cell Differentiation
hPSCs will not be directly utilized for most applications. Typi-
cally, hPSCs would be first differentiated into a desirable cell
population. Ongoing challenges in developing differentiation
paradigms are (1) the need for improved understanding of
the developmental mechanisms underlying the generation of
target cell types, so that lineage specification can be better
recapitulated in vitro via precise manipulation of differentiation
signals, (2) better methods to isolate, capture, and expand
intermediate precursor cell populations to promote controlled
stepwise differentiation, and (3) better methods to promote
the maturation of differentiated cells to match the adult
phenotype.
Chemical approaches have been particularly useful for more
conveniently and precisely tuning differentiation signals, allow-
ing improved synchronization and acceleration of differentiation,
increased differentiation efficiency, and the normalization of the
various differentiation propensities of diverse hPSC lines. For
example, one strategy to synchronize differentiation from each
step and reduce significant heterogeneity in the final desired
differentiated cell population is to expand PSC-derived stage-
specific stem and progenitor cells by small molecules during
the differentiation process (Li et al., 2011). Such strategy pro-
vides a ‘‘check-point’’ to generate more homogenously differen-
tiated functional cell types by skipping PSCs and using pure
intermediate cells as a starting population, thereby removing
some of the differentiation steps required.
Small-molecule modulators of key developmental pathways,
including Wnt, FGF, Hedgehog, Notch, and BMP/TGFb, have
been shown to play essential roles in hPSC differentiation. For
example, based on known mechanisms of neural development
and hESC neuralization, Chambers et al. (2009) showed that
the combination of Noggin protein (a BMP antagonist, which
can be replaced by LDN193189, a small-molecule inhibitor of
the BMP receptor) with SB431542 rapidly and efficiently pro-
motes the neural induction of hPSCs (>80%) in monolayer.
These two inhibitors appear to function synergistically to desta-
bilize hPSC self-renewal, promote neural induction, and block
cell differentiation toward trophectoderm, mesoderm, and endo-
derm lineages (where BMP and TGFb signaling have inductive
effects). Based on this dual-Smad inhibition protocol, they
further demonstrated that floor plate and midbrain dopamine
neurons could be more effectively generated with additional
instructive cues, such as the Hedgehog and Wnt signaling
small-molecule agonists purmorphamine and CHIR99021,
respectively (Fasano et al., 2010; Kriks et al., 2011). More
recently, Chambers et al. also devised a screening of combina-
tions of small molecules with known functions in regulating
essential neural developmental pathways, including TGFb,
BMP, Wnt, FGF, vascular endothelial growth factor (VEGF),
Notch, and Hedgehog. They found that the combination of
five small molecules (including SB431542, LDN-193189,
CHIR99021, SU5402 inhibiting FGFR and VEGFR, and DAPT
inhibiting g-secretase) induced differentiation of hPSCs into
nociceptor neurons in a much accelerated manner with >75%
efficiency within 10 days (Chambers et al., 2012). These studies
suggest that directed PSC differentiation toward a specific line-
age can be achieved by deliberately combining inductive signals
that promote the desired cell lineage with inhibitory signals thatCell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc. 273
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lineages.
Chemical screening approaches have also been useful to
identify novel small molecules that influence stem cell differenti-
ation. For example, phenotypic screens have identified IDE com-
pounds (Figure 2) that could induce definitive endoderm (DE)
differentiation of ESCs (Borowiak et al., 2009) and indolactam
V (Figure 2), a compound that could induce Pdx1 expression
from hESC-derived DE cells (Chen et al., 2009). Cardiac differen-
tiation from hPSCs exhibits significant variation in efficiency
among different hPSC lines, especially in monolayer culture.
To address this challenge, screenings and applications of small
molecules that can enhance cardiac differentiation have proved
to be particularly useful. It had been reported that temporal mod-
ulation of canonical Wnt signaling during development and ESC
differentiation plays a key role in cardiac specification: activation
of Wnt signaling promotes cardiac differentiation at early devel-
opmental stages while it inhibits it later (Naito et al., 2006; Ueno
et al., 2007). Consistent with the earlier findings, several studies
more recently identified or devised conditions withWnt-signaling
small-molecule modulators for more efficient and robust cardiac
differentiation from hPSCs. For example, an aMHC-eGFP
reporter-based screen in monkey ESCs identified a new small
molecule (KY02111; Figure 2) that could promote cardiac induc-
tion when applied on day 4–8 of differentiation after hPSCs were
first treated with CHIR99021 for 3 days. Initial characterization
suggested KY02111 acted downstream of GSK3b to suppress
Wnt signaling, but its precise target remains unknown (Minami
et al., 2012). Similarly, temporal and sequential use of
CHIR99021 and IWR-1endo (Figure 2, a Tankyrase inhibitor
that inhibits Wnt signaling through stabilizing axin) (Gonzalez
et al., 2011) or CHIR99021 and IWP compounds (Figure 2, Por-
cupine inhibitors that inhibit Wnt signaling through blocking
Wnt protein palmitylation and secretion) were developed to
enhance cardiac differentiation of hPSCs (Lian et al., 2012).
These studies suggest that modulation of Wnt signaling (i.e., first
activate to initiate mesoderm induction and then inhibit to facili-
tate cardiac specification) in a precise time window is essential
for efficient cardiac differentiation.
For in vivo applications of PSC-derived lineage-specific cells,
residual undifferentiated PSCs in the population may result in
tumor formation. Aiming to discover pluripotent cell-specific
inhibitors, a high-throughput screening of cell viability using
hESCs was carried out against 52,448 compounds, and primary
hits were counter-screened using hESC derivatives and human
cancer cell lines. Among 15 confirmed hits (named as PluriSIns),
nine compounds share a common structure moiety (phenylhy-
drazine) and the most potent and selective one, PluriSIn#1
(Figure 2), was further characterized. It was revealed that
PluriSIn#1 inhibits stearoyl-CoA desaturase-1 (SCD1) and
specifically induces endoplasmic reticulum stress and cell
apoptosis in pluripotent cells, but not in somatic cell types.
Pretreatment of hESCs with PluriSIn#1 for 48 hr deprived their
ability to form teratomas after being transplanted into immuno-
deficient mice. Not only would PluriSIn#1 be useful for elimi-
nating PSCs when transplanting their derivatives in vivo, as
SCD1 is a key enzyme in oleic acid biosynthesis, this study
also revealed the unique dependence of the pluripotent state
on oleate (Ben-David et al., 2013).274 Cell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc.Small Molecules that Modulate Reprogramming
Induced Pluripotency
The discovery of small molecules that could induce and enhance
the reprogramming of cells to the pluripotent state would offer
several significant advantages over transcription-factor (TF)-
based approaches, including reducing the risks of genetic
manipulation with the oncogenic reprogramming factors,
enhancing reprogramming efficiency, improving the qualities of
generated iPSCs, and changing the process to be directed/
deterministic. A prevailing logic and practical strategy to develop
small-molecule-based reprogramming has been first to identify
both small molecules that can replace each TF and combina-
tions of these reprogramming TFs in different cellular reprogram-
ming contexts (i.e., to use different starting somatic cell types
that endogenously express some of the reprogramming TFs,
have different ectopically expressed TFs, and/or have added
small molecules and growth factors), and then to optimize
sequential and combinatorial treatments with those small mole-
cules to enable reprogramming without any other genetic fac-
tors. In the past several years, significant progress has been
made in that a number of small molecules and their combinations
that functionally substitute for various reprogramming TFs were
identified. In addition, they were shown to significantly enhance
reprogramming efficiency and accelerate reprogramming
speed. Most importantly, characterizations of those small mole-
cules revealed basicmechanisms underlying the reprogramming
process. Based on their mechanisms of action, these small-
molecule reprogramming compounds broadly fall into several
classes, including those that modulate (1) epigenetic protein ac-
tivity, (2) signal transduction pathways, (3) TF activity, and (4) cell
metabolism.
Using phenotypic screens withOct4-GFP expression and col-
ony morphology as selection criteria, BIX-01294 (Figure 2), a
small-molecule inhibitor of the H3K9 histone methyltransferase
G9a (Kubicek et al., 2007), was identified to enable reprogram-
ming with ectopic expression of only Oct4 and Klf4 in somatic
cells.WhenBIX-01294was combinedwith theDNAmethyltrans-
ferase inhibitor RG108 (Figure 2) or the L-type calcium channel
agonist Bayk-8644, fibroblasts could be as efficiently reprog-
rammed using only Oct4 and Klf4 as with the original four TFs
(Shi et al., 2008a, 2008b). Remarkably, BIX-01294 could substi-
tute for Oct4 in the treatment of neural progenitor cells trans-
duced with Sox2, Klf4, and c-Myc. This effect is consistent
with previous findings revealing that repressive H3K9 methyl-
ation is associated with the silencing of pluripotency genes
(such as Oct4 and Rex1) during differentiation (Feldman et al.,
2006) and that histone methylation is dynamic and regulated
by histone methyltransferases and demethylases. BIX-01294
may therefore function to facilitate an epigenetic shift toward plu-
ripotency by unsilencing Oct4 to promote active transcription.
Acetylated histones are associated with active gene expres-
sion. Similarly, histone deacetylase inhibitors (including valproic
acid [VPA] and sodium butyrate), which had been shown in other
cellular contexts to derepress silenced genes, were found to pro-
mote mouse and human somatic cell reprogramming (Huangfu
et al., 2008a, 2008b; Mali et al., 2010). In particular, VPA enabled
human fibroblasts to be reprogrammed with two factors (Oct4
and Sox2) (Huangfu et al., 2008b) and facilitated the reprogram-
ming of mouse fibroblasts into iPSCs using recombinant protein
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addition, parnate (an inhibitor of the H3K4/9 histone demethy-
lase LSD1; Figure 2) and EPZ004777 (an inhibitor of DOT1-like
histone H3 methyltransferase; Figure 2) were identified to pro-
mote the reprogramming of human cells (Li et al., 2009b; Onder
et al., 2012). Interestingly, a recent study suggested that vitamin
C promoted reprogramming in part by modulating Jhdm1a/1b,
two known vitamin-C-dependent H3K36 histone demethylases
that are potent regulators of reprogramming (Wang et al.,
2011a). Consistently, Jhdm1b activation was shown to accel-
erate cell cycle progression and suppress cellular senescence
by repressing the INK4/ARF locus. Another study demonstrated
that aberrant epigenetic silencing of the imprinted Dlk1-Dio3
gene cluster, which was observed in some generated iPSC lines,
could be prevented with vitamin C treatment through indirect
interference with Dnmt3a-mediated hypermethylation of the
Dlk1-Dio3 locus. The presence of vitamin C during reprogram-
ming allowed us to generate high-fidelity iPSCs even from
mature B cells with the capacity to generate all-iPSC mice
through tetraploid complementation (Stadtfeld et al., 2012).
Modulation of cell signaling offers another way to induce and/
or enhance reprogramming. Wnt signaling has been shown to
play important roles in promoting cell proliferation and stem
cell self-renewal (Reya and Clevers, 2005). Among its down-
stream effectors, b-catenin and c-Myc were shown to have pos-
itive effects on reprogramming. Consistent with these findings,
Wnt3a protein was shown to enhance the reprogramming of
mouse fibroblasts in the absence of c-Myc (Marson et al.,
2008). We found that CHIR99021—an inhibitor of GSK3, which
in turn can activate Wnt-b-catenin signaling—enabled the
reprogramming of mouse fibroblasts in the absence of Sox2
and c-Myc (Li et al., 2009b). When combined with parnate,
CHIR99021 facilitated the reprogramming of human keratino-
cytes in the absence of Sox2 and c-Myc. A key feature of reprog-
ramming fibroblasts into iPSCs entails a dramatic phenotypic
change from a spindle mesenchymal-like to a compact
epithelial-like morphology, with concomitant upregulation of
E-cadherin (which is highly expressed in pluripotent cells). This
mesenchymal-to-epithelial-transition (MET) is required for, but
may also represent a barrier to, successful iPSC reprogramming.
Therefore, small molecules that facilitate the MET process were
hypothesized to enhance reprogramming. Indeed, small mole-
cules that target three known MET mechanisms, includ-
ing inhibition of TGFb receptors (by SB431542), MEK (by
PD0325901), or ROCK (by Tzv), significantly enhanced reprog-
ramming efficiency and accelerated reprogramming speed,
when added individually or in combination, by derepressing
the epithelial phenotype via upregulation and stabilization of
E-cadherin expression (Lin et al., 2009). This MET mechanism
was further characterized in three subsequent studies, where
additional small molecules that inhibit the TGFb pathway or up-
regulate E-cadherin were used (Chen et al., 2010b; Ichida et al.,
2009; Maherali and Hochedlinger, 2009). It was shown that TGFb
receptor inhibition by small molecules alone was sufficient to
replace Sox2 during mouse fibroblast reprogramming by facili-
tating the activation of Nanog transcription (Ichida et al., 2009;
Maherali and Hochedlinger, 2009). More recently, another
TGFb receptor inhibitor, A-83-01, combined with a protein argi-
nine methyltransferase inhibitor, AMI-5, enabled the reprogram-ming of mouse fibroblasts transduced with Oct4 alone (Yuan
et al., 2011). Additional signaling pathway modulators, including
a cAMP pathway activator, 8-bromoadenosine 30,50-cyclic
monophosphate (8-Br-cAMP) (Figure 2), and inhibitors of Src
family kinases were shown to induce and promote reprogram-
ming as well (Staerk et al., 2011; Wang and Adjaye, 2011).
Besides regulating epigenetic proteins or signaling pathways
for controlling transcription, targeting nuclear receptors (a class
of ligand-dependent TFs) by small molecules represents a
powerful way to directly modulate transcription. An orphan
nuclear receptor, Nr5a2, was found to replace Oct4 in iPSC
generation in the presence of ectopic expression of Sox2/Klf4/
c-Myc (Heng et al., 2010). Other studies revealed that another
orphan nuclear receptor, Esrrb, plays a key role in ESC self-
renewal and reprogramming to pluripotency. Notably, it was
recently found that ectopic expression of retinoic acid receptor
(RAR) a/g and Nr5a2 greatly enhanced reprogramming effi-
ciency and kinetics. Interestingly, both RARa agonist CD 437
and RARg agonist AM 580 were further shown to significantly
enhance reprogramming (Wang et al., 2011b).
Glycolytic metabolism is advantageous for highly proliferative
cells and stem cells, as it can more effectively produce various
macromolecular precursors to meet metabolic and energy de-
mands while generating fewer reactive oxygen species that
can induce oxidative damage. In addition to transcriptional
rewiring through direct epigenetic and signaling modulation,
metabolic switching from mitochondrial oxidation to glycolysis
represents another fundamental mechanism operant during
iPSC reprogramming. This metabolic reprogramming was
mechanistically revealed when Zhu et al. (2010) characterized
how PS48 (Figure 2), a small-molecule allosteric activator of 30
phosphoinositide-dependent kinase 1, combined with A-83-01,
PD0325901, and sodium butyrate, enabled the reprogramming
of human adult keratinocytes, umbilical vein endothelial cells,
or amniotic fluid-derived cells transduced with Oct4 alone. It
was shown that PS48 exerts its effects at the early stage of
reprogramming by enhancing glycolysis. Consistent with this
finding, a number of small molecules that act more directly on
metabolic pathways and that can promote glycolytic metabolism
also enhance reprogramming, including fructose 2,6-bisphos-
phate (an activator of phosphofructokinase 1), 2,4-dinitrophenol
(an oxidative phosphorylation uncoupler), as well as N-oxaloyl-
glycine and Quercetin (which promotes HIF-1 activity). In
contrast, specific glycolysis inhibitors (e.g., 2-Deoxy-D-glucose
and oxalate) inhibit reprogramming without altering cell prolifer-
ation, which could potentially be used to eliminate undifferenti-
ated PSCs from differentiated cultures. Another concurrent
study confirmed through metabolomic and proteomic analysis
that transition from somatic oxidative metabolism to pluripotent
glycolysis accompanied the reprogramming process. Chemical
inhibition of glycolysis or glucose deprivation blunted reprog-
ramming (Folmes et al., 2011). More recently, a new study
reported success in achieving reprogramming of mouse
fibroblasts to iPSCs using only a cocktail of seven small mole-
cules, including VPA, CHIR99021, 616452 (a TGFb receptor
inhibitor), parnate, forskolin (a cAMP pathway agonist), 3-deaza-
neplanocin A (an S-adenosylhomocysteine hydrolase inhibitor,
blocking histone methylation), and TTNPB (an RAR agonist)
(Hou et al., 2013). Interestingly, all of these compounds, otherCell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc. 275
Table 1. The Comparison of Different Strategies for Regenerative Medicine
Cell Therapy
Enhanced Cell Therapy Via Ex Vivo
Cell Modulation
Chemical or Biologic Therapeutics
Targeting Cells In Vivo
Therapeutic
mechanisms
replace the lost and damaged
cells with healthy ones or
stimulate regeneration via
paracrine mechanisms
replace the lost and damaged cells
with healthy ones with enhanced
capacity of homing, survival, expansion,
differentiation, engraftment, etc.
enhance the endogenous cells to
repair, regenerate, and restore tissues’
normal functions
Immune rejection possible can be ameliorated typically not applicable
Safety potential side effects could be due
to aberrant cell function, cell-borne
contamination, immune reaction,
or cell carcinogenesis potential
potential side effects may be similar
to conventional cell-based therapies
with improved safety and efficacy
potential side effects could be due to
therapeutic molecule’s on-target
mechanism, off-target effects,
and systematic exposure
Feasibility of
development
and use
overall with relatively limited
experiences
may have advantages over conventional
cell-based therapy
overall with extensive experiences
Cost burdens
for patients
relatively high high to low relatively low
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been previously reported in studies looking for small molecules
to replace reprogramming TFs and/or enhance reprogramming,
and target the mechanisms discussed above. To identify the
additional molecule required, Hou et al. screened for com-
pounds that would promote reprogramming at a late stage of
the process and used further refinement to enhance the overall
efficiency. This study represents a major advance in this area
and further supports the logic of small-molecule-based reprog-
ramming initiatives.
Lineage Transdifferentiation
While cellular transdifferentiation had a long history in converting
cells mostly between closely related lineages, iPSC reprogram-
ming strategies (e.g., by employing multiple cell-type-specific
TFs and miRNAs) have catalyzed new advances on reprogram-
ming fibroblasts tomore distantly related or distinct cell lineages,
including functional neurons (Ambasudhan et al., 2011; Caiazzo
et al., 2011; Pang et al., 2011; Pfisterer et al., 2011; Vierbuchen
et al., 2010; Yoo et al., 2011), NSCs (Han et al., 2012), macro-
phage-like cells (Feng et al., 2008), cardiomyocytes, and hepato-
cytes (Huang et al., 2011; Ieda et al., 2010; Sekiya and Suzuki,
2011). Furthermore, direct transdifferentiation in vivo has also
been achieved with ectopic expression of lineage-specific TFs
in situ (Zhou et al., 2008; Qian et al., 2012; Song et al., 2012).
Similar to the iPSC process, transdifferentiation induced by
somatic lineage-specific TFs is slow and inefficient. Based
on the previously reported effects that inhibition of SMAD
signaling and GSK3 by small molecules could promote iPSC
reprogramming and neural induction of human pluripotent
stem cells, Ladewig et al. (2012) recently showed that the effi-
ciency of Ascl1/Ngn2-induced neuronal conversion of human
fibroblasts could be enhanced by the combination of three small
molecules that inhibit GSK3 (by CHIR99021), TGFb receptor
(ALK4/5/7, by SB431542), and BMP receptor (ALK2/3/6, by
LDN193189).
Recently, a new method for transdifferentiation using the
Cell-Activation and Signaling-Directed (CASD) lineage-conver-
sion strategy was established, which employs transient over-
expression of iPSC-TFs (cell activation, CA) in conjunction
with lineage-specific soluble signals (signal-directed, SD) to276 Cell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc.reprogram somatic cells into diverse lineage-specific cell types
without their entrance into the pluripotent state. This concept
and strategy has been demonstrated by direct conversion of
fibroblasts to cardiac, neural, endothelial, and DE precursor
cells using transient expression of iPSC TFs (e.g., over 4 days)
followed by treatment with BMP4 (Efe et al., 2011), FGF4
(Kim et al., 2011), and bFGF/BMP/VEGF (Li et al., 2013). In com-
parison to conventional transdifferentiation, in which different
cell specifications are determined by ectopic expression of
different sets of lineage-specific TFs, CASD-based transdiffer-
entiation might be advantageous in that a single set of TFs is
used for all cell types, and transient gene expression might be
more easily replaced with safer and more convenient methods
without the risk of genetic modifications.
Therapeutic Development for Regenerative Medicine
In addition to conventional cell replacement therapies, emerging
directions for regenerative medicine include (1) transplanted
cells delivering therapeutic molecules through paracrine
signaling to promote the repair/regeneration of target tissue; (2)
ex vivo modulated cell transplants that have enhanced in vivo
functions, including better survival, homing, proliferation, and
differentiation, or secretion of specific functional molecules; (3)
conventional therapeutics (e.g., chemical or biologic drugs)
that can be taken directly by patients and act in vivo to specif-
ically modulate patients’ own cells in the target tissue through
various mechanisms, such as the modulation of cell fate (e.g.,
survival, expansion, differentiation, and reprogramming), cell
behavior (e.g., migration and niche interactions), or cell state/
function (e.g., quiescence and polarization) (Figure 1). The
different therapeutic strategies toward developing regenerative
medicine are compared in Table 1. The discussion below will
focus on recent proof-of-concept advances for using small
molecules in therapeutic applications.
Modulating Stem Cell Trafficking and Homing
Modulating the trafficking of endogenous stem and progenitor
cells for reparative or regenerative therapies via direct cell
replacement or paracrine-based mechanisms represents a
fertile ground for developing powerful therapeutic strategies
that will go well beyond the initial success in the hematopoietic
Figure 3. The Structures and Mechanisms of Representative Chemicals for Modulating Endogenous Stem Cells and Tissue Regeneration
CXCR4, C-X-C chemokine receptor type 4; VLA-4, very late antigen 4; DPP4, dipeptidylpeptidase IV; PGE2, prostaglandin E2; Cdc42, cell division control
protein-42; CBFb, core-binding factor b subunit.
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texts (Miller and Kaplan, 2012; Wagers, 2012).
HSC transplant requires the infusion of a sufficient number
of stem cells able to home to the bone marrow and durably
repopulate the hematopoietic system. At steady state, the vast
majority of HSCs reside in a specialized niche within the
bone marrow, with only a small number of HSCs circulating
throughout the body. However, HSCs can be mobilized into
the peripheral circulation upon exposure to various stimuli.
Currently, hematopoietic stem and progenitor cells (HSPCs)
harvested fromperipheral blood throughmobilization are amajor
source of cells for transplantation. Granulocyte colony-stimu-
lating factor (G-CSF) is the most widely used agent for HSPC
mobilization, and its effects are mediated, at least in part,
through suppression of the C-X-C chemokine receptor type 4
(CXCR-4)/stromal cell-derived factor-1 (SDF-1) retention axis
(Petit et al., 2002). However, the use of G-CSF alone results in
suboptimal stem cell yields in a significant proportion of patients,
thereby precluding autologous transplantation. AMD3100
(Figure 3) is a small-molecule antagonist of CXCR4, and a single
subcutaneous dose could result in a maximum 20-fold increase
in CD34+ cell counts 9 hrs after administration in healthy volun-
teers (Liles et al., 2003). Additional studies showed that the
combination of AMD3100 and G-CSF is superior to G-CSF alone
for HSPC mobilization (Flomenberg et al., 2005). Importantly,
AMD3100 plus G-CSF can mobilize CD34+ cells in non-Hodg-
kin’s lymphoma, multiple myeloma, and Hodgkin’s disease
patients who are refractory to G-CSF-stimulated mobilization
alone (Calandra et al., 2008). Combined with G-CSF, AMD3100
(designated as Plerixafor) is approved by the FDA for HSCmobi-
lization for autologous transplant in non-Hodgkin’s lymphoma
and multiple myeloma patients. In addition to the SDF-1/
CXCR4 axis, the vascular cell adhesion protein 1 (VCAM-1)/a4
integrin (very late antigen 4, VLA-4) axis mediates another impor-tant signaling pathway for HSPC homing and retention in bone
marrow. In mice, BIO5192 (Figure 3), a small-molecule VLA-4 in-
hibitor, increases the mobilization of murine HSPCs 30-fold
above basal levels. BIO5192 could also synergize with
AMD3100 or G-CSF to induce an additive 3-fold or 5-fold
increase, respectively, in stem cell mobilization. Furthermore,
the combination of G-CSF, BIO5192, and AMD3100 has been
shown to enhance mobilization by 17-fold compared with
G-CSF alone. Although the effects of VLA-4 inhibitors on human
HSPC mobilization remain to be studied, these data provide
strong evidence that the combination of agents targeting distinct
mechanisms is a more powerful strategy for HSC mobilization
than single agent alone (Ramirez et al., 2009). Interestingly,
Ryan et al. (2010) recently demonstrated that epidermal growth
factor receptor (EGFR) signaling was negatively correlated
with G-CSF-mediated HSPC mobilization. They also found that
reduction of EGFR activity using genetic approaches or by
treatment with the EGFR inhibitor erlotinib increased HSPC
mobilization, effects that were correlated with downstream
suppression of cell division control protein-42 (Cdc42). These
findings revealed a previously unknown mechanism mediating
HSPC trafficking.
In addition to mobilized stem and progenitor cells as a graft
source for transplantation, in situ mobilized endogenous cells
could be recruited to diseased tissue to stimulate therapeutic
angiogenesis. The SDF-1/CXCR4 axis has been implicated in
homing and retention of HSCs as discussed. CD26/dipeptidyl-
peptidase IV (DPP4) is a membrane-bound extracellular pepti-
dase that cleaves and inactivates SDF-1. Previous studies
showed that inhibition or deletion of DPP4 enhanced the homing
and engraftment of mouse marrow long-term competitive repo-
pulating HSCs in lethally irradiated congenic mice (Christopher-
son et al., 2004). It is worth noting that the SDF-1/CXCR4 axis
represents a general chemotactic mechanism not restricted toCell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc. 277
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major chemokine attracting endogenous endothelial progenitors
that express CXCR4 and home to the injured heart (Askari et al.,
2003). Zaruba et al. (2009) devised a reparative/regenerative
strategy for myocardial infarctionwhereby enhancing the recruit-
ment of G-CSF-mobilized bone marrow stem/progenitor cells to
ischemic heart tissue in vivo by chemical inhibition of DPP4 ac-
tivity led to improved heart function through neovascularization.
In ischemic heart tissue, SDF-1 is a major chemokine that at-
tracts endogenous endothelial progenitors expressing its
cognate receptor CXCR4 to home and localize to the heart.
However, SDF-1 is sensitive to cleavage by a number of pro-
teases (including DPP4). The authors demonstrated that
combined intraperitoneal administration of G-CSF and the
DPP4 inhibitor diprotin A (Figure 3) enhanced the recruitment
of CXCR4+ stem/progenitor cells (including endothelial proge-
nitors) to the myocardium, improved myocardial function by
increasing neovascularization, and increased animal survival.
Previously, DPP4 activity in donor HSCs had been shown to
negatively regulate HSC engraftment after transplantation.
Consequently, ex vivo treatment of HSCs with a DPP4 inhibitor
was demonstrated to enhance HSC homing to the bone marrow
niche and increase the efficiency of HSC transplantation through
preventing SDF-1 cleavage (Christopherson et al., 2004). Clearly,
a better understanding of stem cell trafficking and interaction
within the target niche will lead to improved strategies to fully
harness the therapeutic potential of endogenous stem and pro-
genitor cells. A more recent study showed that SDF-1 also
enhances the expansion of hematopoietic progenitor cells
(HPCs), which can be further enhanced by DPP4 inhibition.
Unexpectedly, this study showed that DPP4 has a more general
role in regulating hematopoietic cytokines. DPP4 cleaves within
the N termini of mouse and human GM-CSF, G-CSF, and eryth-
ropoietin. Truncated cytokines act in a dominant-negative
fashion to inhibit the activity of their full-length counterparts.
Suppression of DPP4 activity by an FDA approved inhibitor,
Sitagliptin, potentiates the activity of hematopoietic cytokines
and accelerates hematopoietic recovery after chemotherapy or
radiation in mice (Broxmeyer et al., 2012).
The manipulation of cytokine receptors is another fruitful
approach to enhance stem cell homing. Through a phenotypic
chemical screen examining HSCs in the zebrafish aorta-
gonad-mesonephros region (where the definitive HSC pool
initially arises), North et al. identified that a number of known
small molecules enhancing prostaglandin E2 (PGE2) synthesis,
including PGE2 itself, were capable of increasing HSC numbers
(Goessling et al., 2009; North et al., 2007). Ex vivo temporal
treatment of murine and human HSCs with 16,16-dimethyl-
PGE2 (dmPGE2; Figure 3), a more stable analog of PGE2,
enhanced their engraftment in vivo possibly by inducing the
transcription of genes involved in HSC homing, including
CXCR4. These findings rapidly led to the design of clinical
studies to test whether ex vivo, dmPGE2-treated human cord
blood cells could improve transplantation outcomes in adult
patients with hematologic malignancies.
Modulating Endogenous Regeneration
and Cell Differentiation
Many lower organisms (e.g., planarian worms and newts)
possess remarkable regenerative capacity upon injury (e.g.,278 Cell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc.complete limb regeneration after amputation). While some
tissues/organs in mammals exhibit significant epimorphic
regeneration upon injury during embryonic and neonatal stages,
many adult tissues/organs utilize tissue-specific stem cells to
maintain homeostasis and exhibit restricted reparative and
regenerative capabilities. Various in vitro reprogramming and
in vivo regeneration studies unambiguously suggest that
mammalian systems retain the intrinsic ability to respond to
appropriate instructive cues to regenerate. Consequently,
studies aimed at identifying these signals and translating them
into regenerative therapeutics that can awaken and orchestrate
a robust regeneration for each tissue type within their niche
drive continued research interests and efforts.
Aged tissues, including their stem cells, do not regenerate
upon tissue attrition or damage as efficiently as in a young
individual, which is correlated with aging-related diseases and
degeneration. Rejuvenation of aged stem cells is therefore an
attractive strategy to prevent and treat these disorders. Recent
mouse studies showed that multiple stem and progenitor cell
types in aged tissues, including the hematopoietic system,
display hyperactivation of Cdc42 in comparison with young
animals (Wang et al., 2007). Cdc42 is a Rho-family GTPase
and plays key signaling roles in cell growth and development,
cytoskeletal reorganization, and cell polarity. It was found that
constitutively increased Cdc42 activity resulted in aging-related
phenotypes in young mouse HSCs, including reduced HSC self-
renewal and homing activity, impaired capacity in supporting
peripheral blood leukocyte numbers, erythropoiesis, and in-
creased contribution of cells to the myeloid lineage, suggesting
a causative role of Cdc42 hyperactivation in HSC aging. Interest-
ingly, young HSCs are polarized cells with asymmetrical distri-
bution of cytoskeletal and polarity proteins together with Cdc42,
while aged HSCs are mainly apolar. Downregulation of Cdc42
activity by the small molecule CASIN (Figure 3) restored
polarity and rejuvenated aged HSC functions in vivo. CASIN
treatment increased histone H4K16 acetylation in LT-HSCs, an
epigenetic feature highly enriched in young LT-HSCs (Florian
et al., 2012).
Adult neurogenesis takes place in mainly two regions in
mammals, the subventricular zone (SVZ) and the subgranular
zone (SGZ) of the hippocampal dentate gyrus. Although the
functional relevance of adult neurogenesis is still being inves-
tigated, evidence showed that neurogenesis is impaired in
aging-related cognitive deficits and in disorders such as
Alzheimer’s disease (AD). Modulating endogenous neurogenesis
may therefore hold promise for the treatment of cognitive
and neurodegenerative diseases. Pieper et al. (2010) recently
reported a study using an impressive in vivo chemical screen
to identify new proneurogenic small molecules in mice. They
tested 1,000 chemicals for their ability to stimulate neurogenesis
in the SGZ. Initially, small pools of 10 compounds were infused
into the left ventricle of adult mice. The effective pools were
further deconvoluted to identify individual active compounds.
One of the compounds, designated as P7C3 (pool 7 compound
3; Figure 3), enhanced the survival of newborn neurons appar-
ently without stimulating neural precursor cell proliferation.
In vivo administration of P7C3 restored morphological and
electrophysiological deficits in the dentate gyrus of mice
lacking neuronal PAS domain protein 3 (Npas3), a critical
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aged rats with P7C3 enhanced neurogenesis and ameliorated
cognitive decline. Although the precise target of P7C3 remains
unknown, P7C3 inhibited apoptosis of newborn neurons and
preserved mitochondrial membrane integrity (Pieper et al.,
2010). Subsequent structural optimization studies of P7C3 led
to the generation of more potent analogs with improved phar-
macokinetic properties (MacMillan et al., 2011), which may
enable subsequent preclinical and clinical studies for treating
neurodegenerative diseases.
In another study, Wang et al. showed that atypical protein ki-
nase C (aPKC) isoforms could regulate the transition of radial
precursors to neurons during embryonic cortical neurogenesis
through activating transcriptional coactivator CREB-binding
protein (CBP). Knockdown of either aPKCz or aPKCi reduced
the neurogenisis of mouse embryonic cortical radial precursors
without influence on their proliferation and apoptosis. Because
a previous study had demonstrated that the antidiabetic agent
metformin can activate the aPKC-CBP pathway through acti-
vation of AMPK in liver (He et al., 2009), they tested whether
metformin could enhance neurogenesis through activation of
the aPKC-CBP pathway. Interestingly, metformin treatment
of in vitro cultured cortical precursors doubled the percentage
of bIII-tubulin-positive neurons in 3 days through activation of
aPKC-CBP pathway. More significantly, administration of met-
formin in vivo increased adult olfactory and hippocampal dentate
gyrus neurogenesis and enhanced spatial memory formation in
adult mice as assessed by a water maze experiment (Wang
et al., 2012). These data are reminiscent of a positive correlation
between dietary restriction and hippocampal neurogenesis (Lee
et al., 2000) and provided insights into the energy metabolism
and neurogenesis.
In addition to protecting endogenous cells and/or promoting
their regeneration, modulating endogenous cell differentiation
in vivo by small-molecule-based therapeutics could also be
used for treating degenerative diseases and injuries. To identify
such lead compounds, in vitro assays using physiologically or
pathologically relevant cells with a disease-modifying pheno-
typic readout could be developed. For example, phenotypic
screening using chondrogenesis as a readout identified a novel
small molecule, kartogenin (KGN; Figure 3), that could induce
the differentiation of chondrocytes from cultured primary human
bone marrow mesenchymal stem cells. Interestingly, KGN could
also protect primary bovine articular chondrocytes and cartilage
explants cultured in the presence of tumor necrosis factor a and
oncostatin M (which induces cytokine-mediated chondrocyte
damage). In a mouse joint injury model, intra-articular adminis-
tration of KGN induced the regeneration of cartilage matrix,
reduced blood-borne pathological markers of cartilage damage,
and alleviated osteoarthritis-induced pain. The efficacy of KGN is
attributed to its chondrocyte-protective effects along with its
ability to direct the chondrogenesis of cartilage-resident mesen-
chymal stem cells. Mechanistic studies revealed that KGN binds
to filamin A, thereby disrupting its interaction with the TF core-
binding factor b subunit (CBFb) in cytoplasm; this leads to the
nuclear localization of CBFb in human mesenchymal stem cells
to regulate the CBFb-RUNX1 transcriptional program. Further
development of KGN-like compounds may lead to novel thera-
pies for treating osteoarthritis (Johnson et al., 2012).Hair cells are postmitotic sensory neurons for the detection of
sound in cochlea and cannot regenerate themselves. Hair cell
loss induced by noise trauma leads to irreversible deafness.
During development, lateral inhibition mediated by Notch sig-
naling has been shown to regulate cell fate determination of
prosensory epithelial cells to generate a balanced mixture of
sensory hair cells and supporting cells. Notch signaling acti-
vation can repress hair cell differentiation factor Atoh1 through
its downstream target Hes5. Jeon et al. (2011) found that
Notch pathway inhibition by g-secretase inhibitors induced hair
cell differentiation of inner ear stem cells in vitro. In a mouse
genetic model with specific and acute hair cell damage, a
follow-up study showed that the inner ear local administration
of a potent g-secretase inhibitor LY411575 (that blocks Notch
pathway; Figure 3) could increase the number of hair cells in
the outer hair cell region in organ of Corti. Interestingly, the
recovery of hair cells was accompanied by the decrease of
supporting cells. Lineage tracing experiments demonstrated
the transdifferentiation of supporting cells into hair cells upon
LY411575 treatment in the mice with acoustic trauma. It remains
to be determined whether the transdifferentiation passes
through a stem cell/progenitor stage. Mechanistically, noise
exposure can transiently activate Notch pathway and upregulate
Hes5 expression in adult mouse cochlea. LY411575 adminis-
tration abolishes Hes5 upregulation and increases the expres-
sion of Atoh1. While these data suggested that LY411575
treatment may be only effective in acute acoustic trauma in the
transient Hes5 upregulation window (Mizutari et al., 2013),
such studies provided a proof-of-principle validation toward
developing hair cell regenerative therapy.
Conclusion
The fields of stem cell research and regenerative medicine are
thriving with breakthrough discoveries and enormous growth in
recent years. In addition, innovative discovery technologies and
new advances in other fields have provided unprecedented op-
portunities to accelerate translation of stem cell biology into ther-
apies. Chemical approaches will continue to play leading roles in
guiding therapeutic developments in regenerative medicine. In
settingswhere endogenous repair and regenerativemechanisms
are not adequate (e.g., acute and massive tissue damage from
disease or injury), cell-based therapies may provide the best
treatment option. In addition, cell-replacement therapies using
functionally and phenotypically identical cells that are generated
to replace cells lost to diseaseor injurywould have superior spec-
ificity compared to conventional therapeutics. Enabling and
improving the generation of such engraftable cells as well as
enhancing their functions in vivo by chemical approaches will
undoubtedly expand cell-based therapies to address many
unmet medical needs. Developing conventional therapeutics to
precisely stimulate endogenous repair and regeneration in vivo
will surely improve convenience and also promises to revolu-
tionize treatments formanydevastating injuries anddegenerative
diseases (Figure 1). Challenges to small-molecule-based
approaches (e.g., specificity, pharmacokinetic properties, and
mechanism-based safety issues)will be addressedbycombining
approaches in conventional drug development with our ever-
improving understanding of stem cell biology and better dis-
covery strategies to identify highly selective and functional cellCell Stem Cell 13, September 5, 2013 ª2013 Elsevier Inc. 279
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Reviewmodulators (e.g., by using the high-throughput and high-defini-
tion screening technology based on sequencing; Li et al., 2012)
or delivery strategies (e.g., antibody-drug-conjugates).ACKNOWLEDGMENTS
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